Enzyme PTP-1B Inhibition Studies by Vanadium Metal Complexes: A Kinetic Approach

Abstract

Abstract The medical field now needs more novel drugs to treat obesity and type-2 diabetes mellitus (T2D) than ever before. Obesity and T2D are both characterized by resistance to the hormones leptin and insulin. PTP-1B is a promising target for drug growth as strong genetic, pharmacological and biochemical evidence points to the possibility of treating diabetes and obesity by blocking the PTP-1B enzyme. Studies have also found that PTP-1B is over expressed in patients with diabetes and obesity, suggesting that inhibiting PTP-1B may be a useful technique in their care. There aren't any clinically used PTP-1B inhibitors, despite the fact that numerous naturally occurring PTP-1B inhibitors demonstrated great therapeutic promise. This is most likely because of their low activity or lack of selectivity. It is still important to look for more effective and focused PTP-1B inhibitors. A few organo vanadium metal complexes were synthesized, characterized, and binding studies on vanadium complexes with PTP-B were also performed using Fluorescence Emission Spectroscopy. Additionally, we theoretically (molecular modeling) and experimentally (enzyme kinetics) examined the PTP-1B inhibitory effects of these vanadium metal complexes and found that they have excellent PTP-1B inhibitory properties.